Genomic Landscape of ER+/HER2-metastatic breast cancer as a function of prior treatment with a CDK4/6 inhibitor

被引：0
|
作者：
Chica-Parrado, M. Rosario
Chica-Parrado, M. Rosario
Lin, Chang-Ching
Mahoney, Timothy
Mauer, Elizabeth
Hanker, Ariella
Arteaga, Carlos
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P5-02-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-02-02
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2-metastatic breast cancer
    Zagami, Paola
    Esposito, Angela
    Salimbeni, Beatrice Taurelli
    Giachetti, Pier Paolo Maria Berton
    Scafetta, Roberta
    Lambertini, Matteo
    Di Maio, Massimo
    Curigliano, Giuseppe
    Criscitiello, Carmen
    Cinieri, Saverio
    BREAST, 2025, 79
  • [2] SIRT3 as a new potential predictive biomarker for response to CDK4/6 inhibition in ER+/HER2-metastatic breast cancer patients
    Manai, Maroua
    Sahraoui, Ghada
    Doghri, Raoudha
    Gerratana, Lorenzo
    D'Amico, Paolo
    Zhang, Youbin
    Donahue, Jeannine
    Shah, Ami
    Reduzzi, Carolina
    Qiang, Wenan
    Cristofanilli, Massimo
    CANCER RESEARCH, 2024, 84 (09)
  • [3] Targeted therapies for ER+/HER2-metastatic breast cancer
    Yamamoto-Ibusuki, Mutsuko
    Arnedos, Monica
    Andre, Fabrice
    BMC MEDICINE, 2015, 13
  • [4] Discovery of CDK4/6 bifunctional degraders for ER+/HER2-breast cancer
    Majeski, Hannah
    Okano, Akinori
    Pasis, Angela
    Carlson, Casey
    Shakya, Arvind
    Huang, Shenlin
    Chourasia, Aparajita Hoskote
    Fung, Leah M.
    Liu, Qiao
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] TREATMENT PATTERNS FOLLOWING FIRST LINE CDK4/6 INHIBITOR PROGRESSION IN HR+, HER2-METASTATIC BREAST CANCER
    Behan, E.
    Bansal, A.
    Veenstra, D.
    VALUE IN HEALTH, 2024, 27 (06) : S406 - S406
  • [6] CDK4/6 INHIBITION IMPROVES SURVIVAL IN ER+, HER2- BREAST CANCER
    不详
    CANCER DISCOVERY, 2015, 5 (02) : 107 - 107
  • [7] Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
    Mai, Nicholas
    dos Anjos, Carlos H.
    Razavi, Pedram
    Safonov, Anton
    Patil, Sujata
    Chen, Yuan
    Drago, Joshua Z.
    Modi, Shanu
    Bromberg, Jacqueline F.
    Dang, Chau T.
    Liu, Dazhi
    Norton, Larry
    Robson, Mark
    Chandarlapaty, Sarat
    Jhaveri, Komal
    NPJ BREAST CANCER, 2024, 10 (01)
  • [8] Utilizing multiomic advanced diagnostics to identify CDK4/6 inhibitor response predictors and a posttreatment multiomic signature for patients with ER+/HER2-metastatic breast cancer (SIDEOUT-3)
    Abu-Khalaf, Mm
    Pierobon, M.
    Denduluri, N.
    Valdes-Albini, F.
    Forero-Torres, A.
    Clark, A.
    Yung, R.
    Mita, M.
    Christensen, S.
    Awerkamp, K.
    Dunetz, B.
    Murphy, R.
    Hatzis, C.
    Zelterman, D.
    Liotta, L.
    Petricoin, E.
    CANCER RESEARCH, 2019, 79 (04)
  • [9] Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HRD/HER2L metastatic breast cancer?
    Giordano, A.
    Lin, N. U.
    Tolaney, M.
    Mayer, L.
    ANNALS OF ONCOLOGY, 2024, 35 (01) : 10 - 14
  • [10] Discovery of CDK4/6 bifunctional degraders for ER+/HER2-breast cancer andtriple negative breast cancer
    Majeski, Hannah
    Okano, Akinori
    Pasis, Angela
    Carlson, Casey
    Liu, Qiao
    Shakya, Arvind
    Huang, Shenlin
    Chourasia, Aparajita Hoskote
    Fung, Leah
    CANCER RESEARCH, 2023, 83 (07)
12345